Monopar Therapeutics Inc.
MNPR
$41.82
-$0.14-0.33%
NASDAQ
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 1.15M | 590.60K | 657.80K | 757.30K | 876.40K |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 11.07M | 1.57M | 1.79M | 1.72M | 1.91M |
Operating Income | -11.07M | -1.57M | -1.79M | -1.72M | -1.91M |
Income Before Tax | -10.93M | -1.30M | -1.72M | -1.64M | -1.81M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -10.93M | -1.30M | -1.72M | -1.64M | -1.81M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -10.93M | -1.30M | -1.72M | -1.64M | -1.81M |
EBIT | -11.07M | -1.57M | -1.79M | -1.72M | -1.91M |
EBITDA | -- | -- | -- | -- | -- |
EPS Basic | -2.23 | -0.37 | -0.49 | -0.51 | -0.62 |
Normalized Basic EPS | -1.39 | -0.23 | -0.31 | -0.32 | -0.39 |
EPS Diluted | -2.23 | -0.37 | -0.49 | -0.51 | -0.62 |
Normalized Diluted EPS | -1.39 | -0.23 | -0.31 | -0.32 | -0.39 |
Average Basic Shares Outstanding | 4.90M | 3.52M | 3.50M | 3.20M | 2.93M |
Average Diluted Shares Outstanding | 4.90M | 3.52M | 3.50M | 3.20M | 2.93M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |